Abstract. F-box and WD repeat domain-containing protein 7 (FBW7), also known as FBXW7, AGO or hCDC4, is an F-box protein with seven tandem WD40 repeats. FBW7 is a key substrate recognition subunit of the Skp1-Cul1-F-box-protein E3 ubiquitin ligase. FBW7 targets for ubiquitination and destruction of numerous crucial transcription factors and protooncogenes, including cyclin E, c-Myc, c-Jun, Notch and MCL-1. FBW7 is a well-characterized tumor suppressor, and its gene is frequently mutated or deleted in various types of human cancer, including colorectal cancer, gastric cancer, ovarian cancer and different types of leukemia. Accumulating evidence indicates that the aberrant expression of FBW7 is involved in the development of hematological tumors, including T cell acute lymphoblastic leukemia, adult T cell leukemia/lymphoma, chronic lymphocytic leukemia and multiple myeloma. The present review will describe the latest findings on the role of FBW7 in hematological tumors, in order to identify a novel target for future therapies.

1. Introduction

The ubiquitin-proteasome system (UPS) is the major regulatory pathway of protein degradation in eukaryotic cells (1). Defects in UPS function can result in several diseases, including cancer (2). F-box and WD repeat domain-containing protein 7 (FBW7), also known as FBXW7, AGO or hCDC4, is an essential component of the Skp1-Cul1-F-box (SCF)-type ubiquitin ligase (E3) complex, which comprises four subunits: Skp1, cullin1, Rbx1 and an F-box protein that determines substrate specificity (3). FBW7 is a well-characterized tumor suppressor, and its gene is frequently mutated or deleted in various types of human cancer, including colorectal cancer, gastric cancer, ovarian cancer and different types of leukemia. Accumulating evidence indicates that the aberrant expression of FBW7 is involved in the development of hematological tumors, including T cell acute lymphoblastic leukemia, adult T cell leukemia/lymphoma, chronic lymphocytic leukemia and multiple myeloma. The present review will describe the latest findings on the role of FBW7 in hematological tumors, in order to identify a novel target for future therapies.

2. Structure and activity of FBW7

The human FBW7 gene is located on chromosome 4 (4q31.3) and encodes three transcripts named FBW7α, FBW7β and FBW7γ (8). The corresponding three proteins possess identical catalytic function but distinct subcellular localizations. FBW7α is mostly localized in the nucleus, whereas FBW7β is found in the cytoplasm and FBW7γ in the nucleolus (9). These three subtypes have different amino acid sequences in the N-terminal region but contain conserved interaction regions (F-box and WD40 repeats) in the C-terminal region (9-11). All isoforms share three essential domains that have distinct functions: i) D domain; ii) F-box domain and iii) seven tandem WD40 (tryptophan-aspartic acid 40) repeats (9) (Fig. 2). The D domain promotes FBW7 dimer-
ZHU et al.: FBW7 IN HEMATOLOGICAL TUMORS

1658

The F-box domain is necessary for direct binding of FBW7 to Skp1, enabling the recruitment of other components of SCF (9). The WD40 repeats are required for substrate recognition (12).

The target proteins degraded by FBW7 contain a conserved sequence of phosphorylated amino acids named CDC4 phosphodegron (CDP). CDPs bind to the WD40 repeats, allowing the recognition of the substrate by ubiquitin ligase for its subsequent degradation (10). Furthermore, dimerization of FBW7 increases the binding of FBW7 to substrates, particularly to those with weak phosphodegrons (13). In addition, glycogen synthase 3β (GSK3β) serves a crucial role in the degradation of substrate by FBW7. GSK3β catalyzes the phosphorylation of threonine in the substrate CDPs, promoting FBW7 binding and accelerating the degradation of the substrate (14,15) (Fig. 2).

3. Substrates of FBW7 in cancer

FBW7 is an important substrate adaptor responsible for recognition and binding of the substrate proteins in the ubiquitin-proteasome degradation pathway. Many of its substrates are oncogenes. For example, c-Myc is an important substrate for ubiquitination by FBW7 (16,17).

In general, decreased expression of FBW7 results in a significant increase in the intracellular content of c-Myc protein, whereas overexpression of FBW7 promotes c-Myc ubiquitination and degradation, decreasing its cellular level (14). In the Burkitt's lymphoma cell line, c-Myc is most commonly mutated at T58, causing the failure of FBW7 to regulate c-Myc protein degradation, ultimately leading to c-Myc protein accumulation and tumorigenesis (14). Cyclin E is another classical substrate of FBW7. By binding to cyclin E-dependent kinase 2 (CDK2), cyclin E forms a complex that promotes the G/S phase transition, leading to uncontrolled cell proliferation (18). FBW7 can also ubiquitinate various other target proteins, including Notch1 (19), NF-κB (20), c-Jun (21), granulocyte colony stimulating factor receptor (22), SHOC2 leucine rich repeat scaffold protein (23), brahma-related gene-1 (24), Aurora A (25), Kruppel like factor 5 (26), heat shock transcription factor 1 (27) and CCAAT/enhancer-binding protein α (28) (Table I).

4. Regulation of FBW7

The main mechanisms of FBW7 disruption in cancer are deletion, mutation and promoter methylation (29-31) and the gene mutation is the most common. A previous study demonstrated that FBW7 is mutated in ~6% of human tumors, and in 31%
of acute T-cell lymphocytic leukemia cases (32). It has been demonstrated that conditional FBW7 knockout in the T-cell lineage of mice leads initially to thymic hyperplasia and subsequently to the development of thymic lymphoma, indicating that the loss of FBW7 function is an important factor responsible for tumorigenesis in the blood system (33). In addition, FBW7 expression and activity can be regulated by numerous genes, including p53 (34). FBW7 is a p53-depen-
dent tumor suppressor, and p53 activation can enhance the ubiquitination-mediated degradation of oncoproteins (34). Furthermore, previous studies have identified numerous micro (mi)RNAs that can regulate FBW7 expression, including miR-223 (35), miR-25 (36), miR-182 (37), miR-503 (37) and miR-92a (38). In addition, in T-cell acute lymphoblastic leukemia (T-ALL), miR-223 acts as an oncogene by inhibiting the FBW7 expression. The expression of FBW7 is also controlled by the RBP-J-interaction and tubulin-associated (RITA) protein. Overexpression of RITA results in increased expression of FBW7 and decreased expression of cyclin E, cyclin D1, CDK2, Hes-1 and NF-kBp65 (39). In addition, NF-κB1 (40), Pin1 (41), family with sequence similarity 83 member D (FAM83D) (42) and Numb4 (43) are also regulators of FBW7 expression (Table II).

5. FBW7 mRNA expression in different types of human cancer

In order to determine whether FBW7 is differently expressed in tumor tissues compared with normal tissues, the Oncomine database (https://www.oncomine.org) was used to analyze FBW7 mRNA levels in different tumor and normal tissues. The results indicated that FBW7 expression is higher in leukemia (Fig. 3A), suggesting that FBW7 may be associated with the initiation and progression of certain hematological tumors. The Timer database (https://cistrome.shinyapps.io/timer/) was then used to analyze FBW7 mRNA levels in diffuse large B cell lymphoma (DLBCL). The result demonstrated no significant difference in FBW7 expression level in DLBCL. This may be due to different expression levels of FBW7 in various hematological tumors (Fig. 3B).

6. Role of the FBW7 gene in common hematological tumors

T-ALL. T-ALL is a highly proliferative hematologic malignancy caused by the malignant transformation of T-cell progenitors (44). Patients with T-ALL typically present with aggressive clinical features correlated with poor prognosis, including inhibition of normal hematopoietic function, high white blood cell counts, pleural effusions and central nervous system involvement (45). T-ALL accounts for 15 and 25% of the total number of childhood and adult cases of acute lymphoblastic leukemia, respectively (46). The rate of T-ALL development is accelerated by the simultaneous loss of p53 or Phosphatase and TENsin homolog or by concurrent activation of other tumor-promoting factors (49,50). Furthermore, T-ALL development is accelerated by the simultaneous loss of p53 or Phosphatase and TENsin homolog or by concurrent activation of Notch (49,51,52). However, Notch1 alone is not sufficient to induce or maintain T-ALL in the absence of other tumor-promoting factors (49,50).
of c-Myc function; however, c-Myc deletion in established T-ALL specifically ablates leukemia-initiating cells (LIC), and the inhibition of c-Myc induction by small molecule inhibitors of bromodomain and extra-terminal motif/bromodomains can suppress the proliferation of mouse and human T-ALL cells, suggesting that c-Myc could be considered as a key oncogene driving T-ALL (53). It was reported that >60% of T-ALL cases present with abnormal activation of the Notch1 signaling pathway, indicating that Notch1 might be the most common oncogene in T-ALL (55). Mutations of Notch1 occur mainly in the heterodimeric domain region and the proline, glutamine, serine, and threonine domain (56,57). Activating mutations of Notch1 gene result in sustained expression of genes regulating T cell differentiation, including Hes family bHLH transcription factor 1 and CD25, changing the expression balance of c-Myc and p27 (58-60), upregulating the NF-κB signaling pathway (5), enhancing the expression of the anti-apoptotic X-linked inhibitor of apoptosis protein associated with ubiquitination and degradation, and activating the PKB/Akt/mTOR signaling pathway-mediated inhibition of p53 (61). All the aforementioned signaling pathways inhibit apoptosis and cause abnormal proliferation of non-functional T cells, thereby directly leading to the development of T-ALL. In addition, Notch and NF-κB bind to the promoter of miR-223, activating its expression (62). Notch-mediated upregulation of miR-223 subsequently inhibits FBW7 gene expression in T-ALL, and miR-223 and FBW7 expression are negatively correlated in T-ALL patient-derived xenografts (62). In addition, it has been demonstrated that FBW7 loss of function leads to an upregulation of the glucocorticoid

| Table I. Factors regulated by FBW7. |
|-------------------------------------|
| **Author, year** | **Factors** | **Function** | **Reference** |
|-------------------------------------|
| Yada et al, 2004 | c-Myc | Transcription factor that regulates the expression of many genes | (16,17) |
| Welcker et al, 2004 | Cyclin E | Regulates cell-cycle entry and progression | (18) |
| Koepp et al, 2001 | Notch1 | Transcriptional regulators of cell fate and differentiation | (19) |
| Weng et al, 2004 | NF-κB | Important factor in many fundamental cellular processes | (20) |
| Fukushima et al, 2012 | c-Jun | Transcription factor which regulates the cell cycle | (21) |
| Wei et al, 2005 | G-CSF | Controls the production, differentiation, and function of granulocytes | (22) |
| Xie et al, 2019 | SHOC2 | Involved autophagy induction and cell survival | (23) |
| Huang et al, 2018 | BRG1 | Involved in governing chromatin structure and gene transcription | (24) |
| Finkin et al, 2008 | Aurora-A | Involved in the cell mitosis and cell cycle regulatory process | (25) |
| Liu N et al, 2010 | KLF5 | Promotes differentiation and self-renewal of fat cells | (26) |
| Kourtis et al, 2015 | HSF1 | Regulates the heat-shock response and supports malignancy | (27) |
| Bengoechea-Alonso et al, 2010 | C/EBPα | Involved in lipid metabolism | (28) |

| BRG1, brahma-related gene-1; C/EBPα, CCAAT/enhancer-binding protein α; HSF1, heat shock transcription factor 1; KLF5, Kruppel like factor 5; SHOC2, SHOC2 leucine rich repeat scaffold protein. |

| Table II. Factors regulating FBW7. |
|-------------------------------------|
| **Author, year** | **Factors** | **Activator/Inhibitor** | **Reference** |
|-------------------------------------|
| Kimura et al, 2003 | p53 | Activator | (34) |
| Mansour et al, 2013 | miRNAs | Inhibitor | (35-38) |
| Xiang et al, 2015 | RITA | Inhibitor | (39) |
| Li et al, 2014 | NF-κB1 | Inhibitor | (40) |
| Zhou et al, 2015 | Pin1 | Inhibitor | (41) |
| Wang et al, 2014 | FAM83D | Inhibitor | (42) |
| Jiang et al, 2012 | Numb4 | Activator | (43) |

| FAM83D, family with sequence similarity 83 member D; miRNA, microRNA; RITA, RBP-J-interaction and tubulin-associated protein. |
receptor in primary T-ALL cells, thereby enhancing their sensitivity to glucocorticoids and improving the prognosis of patients with T-ALL (63). MCL-1 is an anti-apoptotic protein of the BCL-2 family that promotes cancer by inhibiting apoptosis (64). Deletion of FBW7 in T-ALL cell line results in an increased expression level of MCL-1. MCL-1 upregulation is sensitive to various kinase inhibitors, including sorafenib, but resistant to the BCL2 inhibitor ABT-737. However, when FBW7 function is restored or MCL-1 is deleted, cell sensitivity to ABT-737 is restored (65). MCL-1 also serves a role in the chemotherapy efficacy of anti-tubulin drugs. Treatment with paclitaxel and similarly acting compounds induces MCL-1 phosphorylation, which is then recognized by FBW7 and degraded by ubiquitination. Subsequently, the intracellular MCL-1 protein content is significantly decreased and promotes therefore apoptosis. In addition, when FBW7 is inactivated or downregulated in the tumor, the stability of MCL-1 protein is enhanced, thereby increasing resistance of the tumor to microtubule-targeted drugs and decreasing the effectiveness of chemotherapy (66). The cellular content of MCL-1 protein is also affected by the deubiquitinating enzyme named ubiquitin specific peptidase 9 X-Linked (USP9X) (67). Since USP9X decreases the ubiquitination of MCL-1 and increases its stability, USP9X downregulation and decreased MCL-1 protein expression could increase tumor cell sensitivity to ABT-737 treatment.

Adult T cell leukemia/lymphoma (ATL). ATL is a malignant T cell monoclonal proliferative disease caused by the human T-cell leukemia virus type 1 (HTLV-1). ATL represents a rare type of lymphocytic leukemia/lymphoid tumor affecting T cells (68). FBW7 acts as a tumor suppressor in ATL cells; however mutations can transform FBW7 into an oncogenic protein (69). Mutations in the WD40 domain of FBW7 were identified in 25% (8/32) of acute ATL cases (69). Furthermore, the FBW7 D510E and D527G mutants are capable of ubiquitinating proteolysis of endogenous cyclin E, MCL-1, and c-Myc. However, these mutants are ineffective in degrading the Notch intracellular domain (NICD) in ATL cells, resulting in the activation of Notch1 signaling. The increased Notch1 signaling can subsequently promote ATL cell proliferation and tumorigenesis (69). The same mutants present significant carcinogenic activity when co-expressed with HTLV-1 Tax, mutated p53 R276H or c-Myc38C (69). In addition, previous studies reported the downregulation of FBW7 expression in ATL, which leads to c-Myc accumulation and initiation of ATL cell proliferation (70). The c-Myc-FBW7 axis pathway could therefore represent a potential target for the treatment of ATL.

Chronic lymphocytic leukemia (CLL). CLL is the most common type of leukemia in Western countries (71). CLL is primarily characterized by the accumulation of monoclonal CD5+ mature B cells in lymphoid tissues and peripheral blood (72). Despite significant advances in its treatment, CLL remains incurable (73). In CLL, the mutation rate of FBW7 is 2-6% (74-76), and these mutations are associated with chromosome 12 trisomy aberrations of mature CD19+ B cells (75). A previous study identified FBW7 mutations in 36 out of 905 untreated patients with CLL. All these mutations are heterozygous, missense in 78% of cases and primarily affect the
substrate-binding domain of WD40 (77). Furthermore, 10% of the mutations were located on the first exon of the α-transcript. In order to identify the target protein of FBW7 in CLL, a WD40 domain-truncated CLL cell line (HG-3) was generated using the CRISPR/Cas9 method (77). Homozygous truncation of FBW7 results in increased levels of activated Notch1-NICD and c-Myc proteins, and in enhanced activity of HIF1-α (77). In primary cells derived from patients with CLL carrying the FBW7 mutation, the level of activated Notch1-NICD was elevated and remained stable after inhibition of translation (77). In addition, FBW7 mutation was combined with enhanced expression of Notch1 target genes (77). FBW7 mutations in CLL cells may therefore explain the dysregulation of Notch1 signaling in certain patients with CLL, indicating that FBW7 could be a cancer-driving gene in CLL.

Multiple myeloma (MM). MM, which is an incurable malignant plasma cell disease, is one of the most common hematological malignancies in adults, accounting for 15% of malignant hematological tumors (78). MM is primarily characterized by clonal proliferation and abnormal accumulation of plasma cells in the bone marrow, combined with the secretion of a large number of monoclonal immunoglobulins (79). The etiology of MM is complex. NF-κB may serve a crucial role in supporting MM cell survival. The NF-κB signaling pathway is activated in the majority of patients with MM, whereas NF-κB signaling pathway blockage using some inhibitors of NF-κB kinase subunit β (IKK2) can inhibit MM cell proliferation (80,81). In non-canonical NF-κB pathway, IKKα is activated by NIK and directly phosphorylates p100. Phosphorylated p100 is therefore degraded in a 26S proteasome-dependent manner (82). It has been demonstrated that p100 degradation in the nucleus is crucial to activate the non-canonical NF-κB pathway (83). During this reaction, FBW7 recognizes the CPD sequence of p100 and promotes p100 degradation in a GSK-3 phosphorylation-dependent manner (15). Furthermore, FBW7 overexpression enhances the activity of NF-κB, whereas FBW7 downregulation can upregulate p100 expression (15). In MM, FBW7 silencing leads to an increased expression of p100 and partly activates MM cell apoptosis (15,84). FBW7 may therefore be an oncogene in MM. In addition, fibroblasts from patients with MM are crucial in the progression of the disease and in drug resistance (85,86). For example, it was demonstrated that miR-27b-3p is significantly upregulated in the fibroblasts of bone marrow from patients with MM where it controls FBW7 activity, which in turn regulates MCL-1 that can promote fibroblast proliferation (87).

7. Conclusions and perspectives

FBW7 is an important tumor suppressor that regulates multiple oncogenes, including cyclin E, c-Myc, Notch, c-Jun and mTOR. In addition, FBW7 is regulated by p53, certain miRNAs, including miR-223, miR-25, miR-182, miR-503 and miR-92a, RITA, FAM83D and Numb4. Mutation, deletion and hypermethylation are the main mechanisms of FBW7 disruption in cancer, leading to tumor progression. Mutation of FBW7 may promote tumorigenesis and increase the tumor resistance to chemotherapy. Furthermore, the carcinogenic effects of FBW7 have also been identified in certain types of hematological tumor, including ATL and MM. These findings have important implications for the understanding of hematopoietic mechanisms, development of diagnostic reagents, and design and optimization of therapeutic drugs. The detection of FBW7 mutations is clinically relevant, and FBW7 could serve as a potential target for the treatment of hematological tumors. Further investigation into FBW7 mutations will have a positive impact on the prevention of hematological tumors and the development of personalized treatments.

Acknowledgements

Not applicable.

Funding

The present study was supported by the National Science and Technology Major Project for New Drug (grant no. 2017ZX301033), the National Natural Science Foundation of China (grant nos. 81874049, 81602179 and 81570198), the Co-construction of Provincial and Department Project (grant no. WKJ-ZJ-1919) and the Zhejiang Provincial Natural Science Foundation of China (grant no. LY19H160036).

Availability of data and materials

The datasets used and/or analyzed during the present study are available from the corresponding author upon reasonable request.

Authors’ contributions

QZ, LH, XT and QX conceived and designed the review. YG wrote the manuscript. YG collected and assembled the data presented in Tables I and II. QZ and LH designed the figures. QZ and LH collected and assembled the data present in Tables I and II, QZ and LH designed the figures. QZ and LH wrote the manuscript. YG collected and assembled the data present in Tables I and II, ZW was involved in designing the figures and analysing the data of figure 3. All authors approved the final version of the manuscript.

Ethics approval and consent to participate

Not applicable.

Patient consent for publication

Not applicable.

Competing interests

The authors declared that they have no competing interests.

References

1. Herskho A, Ciechanover A and Varshavsky A: The ubiquitin system. Nat Med 6: 1073-1081, 2000.
2. Crisso KM, King B, Reavie LB and Aifantis I: The ubiquitous nature of cancer: The role of the SCF(Fbw7) complex in development and transformation. Oncogene 29: 4865-4873, 2010.
3. Shimizu K, Nihira NT, Iinuzuka H and Wei W: Physiological functions of FBW7 in cancer and metabolism. Cell Signal 46: 15-22, 2018.
4. Uddin S, Bhat AA, Krishnakutty R, Mir F, Kulinski M and Mohammad RM: Involvement of F-BOX proteins in progression and development of human malignancies. Semin Cancer Biol 36: 18-32, 2016.

7. Tan Y, Sangfelt O and Spruck C: The Fbxw7/hCdc4 tumor suppressor targets proproliferative factor KLF5 for ubiquitination and degradation through multiple phosphodegron motifs. J Biol Chem 285: 18858-18866, 2010.

20. Fukushima H, Matsumoto A, Inuzuka H, Zhai B, Lau AW, Lau N, Li H, Li S, Shen M, Xiao N, Chen Y, Wang Y, Wang W, Lu Z, Wang X, Lu Z, Lu S, Oren M and Alboed B: Early T-cell precursor leukemia/lymphoma in adults and children. Leuk Res 37: 1027-1034, 2013.

22. Lochab S, Pal P, Kapoor I, Canavari JK, Sanyal S, Behre G and Trivedi AK: E3 ubiquitin ligase FBW7 regulates cell cycle arrest and apoptosis in colon carcinoma by activating the p53-FBW7 pathway. Biochem J 471: 2019-2029, 2019.

44. Peirs S, Van der Meulen J, Van de Walle I, Taghon T, Speleman F, Park PJ, Thibodeau SN, Steer CJ and Subramanian S: Sequential expression of miR-182 and miR-903 cooperatively targets FBXW7, contributing to the malignant transformation of colon adenoma to adenocarcinoma. J Pathol 234: 488-501, 2014.

45. Pui CH and Evans WE: Treatment of acute lymphoblastic leukemia in infants. Immunol Rev 263: 50-67, 2015.

47. Allen A, Sireci A, Colovai A, Pinkney K, Sulis M, Bhagat G and Alobeid B: Early T-cell precursor leukemia/lymphoma in adults and children. Leuk Res 37: 1027-1034, 2013.
Inuzuka H, Shaik S, Onoyama I, Gao D, Tseng A, Maser RS, Malyukova A, Brown S, Papa R, O'Brien R, Giles J, Trahair TN, Matsuoka S, Oike Y, Onoyama I, Iwama A, Arai F, Takubo K, Kwon YW, Kim IJ, Wu D, Lu J, Stock WA Jr, Liu Y, Huang Y, Onoyama I, Tsunematsu R, Matsumoto A, Kimura T, de Alborán IM, Pui CH, Robison LL and Look AT: Acute lymphoblastic leukemia. J Exp Med 205: 1395-1408, 2008.

Arruga F, Gizdric B, Bologna C, et al: Mutations in NOTCH1 PES2 domain drive COL11A1-driven homing of chronic lymphocytic leukemia cells by modulating the tumor suppressor gene DUSP22. Cell 153: 1552-1563, 2013.

Chiang MY, Radiocic V and Maillard I: Oncogenic Notch signaling in T-cell and B-cell lymphoproliferative disorders. Cell 160: 362-370, 2015.

Grabher C, von Boehmer H and Look AT: Notch1 activation in the molecular pathogenesis of T-cell acute lymphoblastic leukemia. Nat Rev Cancer 6: 199-210, 2013.

Arruga F, Gizdric B, Bologna C, et al: Mutations in NOTCH1 PES2 domain drive COL11A1-driven homing of chronic lymphocytic leukemia cells by modulating the tumor suppressor gene DUSP22. Cell 153: 1552-1563, 2013.

Chiang MY, Radiocic V and Maillard I: Oncogenic Notch signaling in T-cell and B-cell lymphoproliferative disorders. Cell 160: 362-370, 2015.

Grabher C, von Boehmer H and Look AT: Notch1 activation in the molecular pathogenesis of T-cell acute lymphoblastic leukemia. Nat Rev Cancer 6: 199-210, 2013.

Katsuya H, Ishitsuka K, Utsunomiya A, Hanada S, Eto T, Moriiuchi Y, Saburi Y, Miyahara M, Sueoka E, Uike N, et al: The NOTCH signaling pathway in chronic lymphocytic leukemia. Blood 126: 2570-2577, 2015.

Yeh J-H, Bellon M, Pancewicz-Dembicka J and Nicot C: Oncogenic mutations in the FBXW7 gene of adult T-cell leukemia/lymphoma. Proc Natl Acad Sci USA 113: 6731-6736, 2016.

Mihashi Y, Mizoguchi M, Takamatsu Y, Ishtsuka K, Iwasaki H, Koga M, Urake B, Momosaki S, Sakata T, Kiyomi F, et al: C-MYC and its main ubiquitin ligase, FBXW7, influence cell proliferation and apoptosis of adult T-cell leukemia/lymphoma. Am J Surg Pathol 41: 1139-1149, 2017.

Chiorazzi N, Rai KR and Ferrari M: Chronic lymphocytic leukemia. N Engl J Med 352: 804-815, 2005.

Kipps TJ, Stevenson FK, Wu CJ, Croce CM, Packham G, Wierda WG, O'Brien S, Gribben J and Rai K: Chronic lymphocytic leukemia. Annu Rev Med 58: 295-315, 2007.

Bosch F and Dalla-Favera R: Chronic lymphocytic leukemia: From genetics to treatment. Nat Rev Clin Oncol 16: 684-701, 2019.

Landau DA, Tausch E, Taylor-Weiner AN, Stewart C, Reiter JG, Bahl J, Kluth S, Bozie I, Lawrence M, Böttcher S, et al: Mutations driving clonal evolution and relapse. Nature 526: 525-530, 2015.

Jeronim S, Weissmann S, Hafeler C, Dicker F, Bayer G, Grossmann V, Alперман T, Roll A, Kohlmann A, Hafeler T, et al: SF3B1 mutations correlated to cytogenetics and mutations in NOTCH1, FBXW7, MYD88, XPO1 and TP53 in 1160 untreated CLL patients. Leukemia 28: 108-117, 2014.

Quijada-Alamo M, Hernández-Sánchez M, Robledo C, Hernández-Sánchez JM, Benito R, Montaño A, Rodríguez-Vicente AE, Quwaider D, Martin AA, García-Alvarez M, et al: Next-generation sequencing and FISH studies reveal the appraisement of gene mutations and chromosomal abnormalities in hematopoietic progenitors in chronic lymphocytic leukemia. J Hematol Oncol 10: 83, 2017.

Close V, Close W, Kugler SJ, Reichenzeller M, Yosifov DY, Bloedhorn J, Pan L, Tausch E, Westhoff MA, Döner H, et al: FBXW7 mutations and NOTCH1 binding of NOTCH1, leading to cleaved NOTCH1 accumulation and target gene activation in CLL. Blood 133: 830-839, 2019.

Palumbo A and Anderson K: Multiple myeloma. N Engl J Med 364: 1046-1060, 2011.

Somerveld P, Aver-Loiseau H, Lonial S, Usman I, Siegel D, Anderson KC, Chng WJ, Moreau P, Attal M, Kyle RA, et al: Treatment of multiple myeloma with high-risk cytogenetics: A consensus of the International Myeloma Working Group. Blood 127: 2955-2962, 2016.

Anzurnaeta CM, Davis RE, Demchenko Y, Bellamy W, Gabreia A, Zhan F, Lenz G, Hanamura I, Wright G, Xiao W, et al: Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cell 12: 115-130, 2007.

Jourdan M, Moreaux J, De vos J, Hose D, Mahtook K, Abouladze M, Robert N, Boulard M, Rème T, Romanelli A, et al: Targeting NF-kappaB pathway with an IKK2 inhibitor induces inhibition of multiple myeloma Cell Proliferation. Br J Haematol 138: 160-168, 2007.

Sun SC: The non-canonical NF-κB pathway in immunity and inflammation. Nat Rev Immunol 17: 545-558, 2017.

Sentiﬂenleb I, Cao Y, Xiao G, Gritzen FR, Krahn G, Bonizzi G, Chen Y, Hu Y, Fong A, Sun SC, et al: Activation by IKKα/IKKβ of a second, evolutionary conserved, NF-kappaB signaling pathway. Science 293: 1495-1499, 2001.

Busino L, Millman SE and Pagano M: SCF-mediated degradation of p100 (NF-κB2): Mechanisms and relevance in multiple myeloma. Sci Signal 5: pt14, 2012.

Frassanito MA, Rao L, Moschetta M, Ria R, Di Marzo L, Abouladze M, Robert N, Boulard M, Réme T, Romanelli A, et al: Targeting NF-kappaB pathway with an IKK2 inhibitor induces inhibition of multiple myeloma Cell Proliferation. Br J Haematol 138: 160-168, 2007.

Frassanito MA, De Veirman K, Desantis V, Di Marzo L, Vergara D, Ruggieri S, Annese T, Nico B, Menu E, Catalìo I, De Luisi A, Racanelli V, et al: Targeting NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma. Sci Signal 5: pt14, 2012.